Biotech Bulls & Breakthroughs Titelbild

Biotech Bulls & Breakthroughs

Biotech Bulls & Breakthroughs

Von: BioPharmCatalyst
Jetzt kostenlos hören, ohne Abo

Über diesen Titel

Welcome to Biotech Bulls & Breakthroughs! This brand new podcast from BioPharmCatalyst explores the dynamic world of biotech investing alongside long-time biotech trader Sheff from Sheff Station. Each month, we will be discussing current events in the biotech industry and how these events impact investors, as well as a discussion of upcoming catalysts in the biotech space.

© 2026 Biotech Bulls & Breakthroughs
Persönliche Finanzen Politik & Regierungen Wissenschaft Ökonomie
  • Navigating the Future of Biotech: Insights from the JP Morgan Healthcare Conference 2026
    Jan 22 2026

    In this episode, as the biotech landscape continues to evolve, the recent JP Morgan Healthcare Conference 2026 has set the stage for an exciting year ahead. John Gagliano and Sheff Sheffield delve into the key takeaways from the conference, exploring significant acquisitions, emerging trends, and the role of artificial intelligence in shaping the industry's future.

    In this episode:
    🔹 Growth areas in immunology, metabolism, neurology, and oncology will drive the industry forward in 2026.
    🔹 China’s growing role in the market necessitates collaboration with U.S. companies for enhanced innovation.
    🔹 AI is becoming a transformative force in biotech, expediting drug discovery and product development.

    Sheff is proud to support the Northwest Association for Blind Athletes. Join us in empowering life-changing opportunities for visually impaired youth and adults through sports and community engagement. You can support this as well in the link below:
    Support NWABA: https://nwaba.org/support/other-ways-to-help/sheffstation/#join-sheff-station

    🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar
    🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast
    📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades

    📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst
    📲 Follow Sheff: https://x.com/SheffStation

    Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.

    Mehr anzeigen Weniger anzeigen
    50 Min.
  • 2025 Biotech Recap & Set Up For 2026
    Dec 11 2025

    In this episode, John Gagliano and Chef Sheffield review the biotech landscape of 2025, discussing key trends, FDA clarity, and the impact of CRLs on investor confidence. They highlight significant companies and catalysts to watch as they transition into 2026, emphasizing the importance of institutional investments and upcoming events that could shape the market.

    In this episode:
    🔹 2025 saw increased clarity from the FDA
    🔹 The upcoming JP Morgan conference will set the stage for 2026
    🔹 CRLs are not the end

    🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar
    🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast
    📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades

    📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst
    📲 Follow Sheff: https://x.com/SheffStation

    Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.

    Mehr anzeigen Weniger anzeigen
    48 Min.
  • Understanding Catalysts in Biotech Trading
    Oct 30 2025

    In this episode, John Gagliano and Sheff Sheffield discuss the current state of the biotech market as they approach the end of the year. They reflect on recent trading successes and challenges, emphasizing the importance of understanding catalysts and market reactions. The conversation also highlights the significance of insider trading and institutional movements in stock performance. Finally, they explore upcoming catalysts and provide insights into their stock watchlist for the remainder of the year. In this conversation, CS (Sheff) Sheffield discusses various emerging biotech companies and their upcoming clinical trials, data releases, and market implications. He highlights the significance of low float stocks, the potential for substantial market movements based on positive data, and the importance of regulatory pathways in the biotech industry. The discussion also covers specific companies, their innovative therapies, and the competitive landscape in the pharmaceutical market, particularly focusing on PDUFA dates and biosimilars.

    In this episode:
    🔹 Institutional buying can greatly influence stock prices.
    🔹 Low float stocks can lead to significant price movements.
    🔹 Patience is crucial when waiting for 510k approvals.

    Sheff is proud to support the Northwest Association for Blind Athletes. Join us in empowering life-changing opportunities for visually impaired youth and adults through sports and community engagement. You can support this as well in the link below:
    Support NWABA: https://nwaba.org/support/other-ways-to-help/sheffstation/#join-sheff-station

    🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar
    🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast
    📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades

    📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst
    📲 Follow Sheff: https://x.com/SheffStation

    Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.

    Mehr anzeigen Weniger anzeigen
    50 Min.
Noch keine Rezensionen vorhanden